Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer drug trial halted: REC-4881 fails to show promise in Gene-Mutated tumors

NCT ID NCT06005974

Disease control Sponsor: Recursion Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a daily pill called REC-4881 in 18 adults aged 55+ with advanced solid tumors that had AXIN1 or APC gene mutations. The goal was to see if the drug could shrink tumors or slow cancer growth. The trial was stopped early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

18 people

The number who actually took part.

Started

Jan 2024

Finished

Feb 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. 55 years of age or older with histologically-confirmed unresectable, locally advanced, or metastatic solid tumor with AXIN1 or APC mutation. If a participant has colorectal cancer, then they must be RAS / RAF wild type to enroll into the APC mutant cohort 2. Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment, or in the opinion of the Investigator have been considered ineligible for standard therapy 3. Measurable disease at baseline per RECIST 1.1 criteria 4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 Exclusion Criteria: 1. Received treatment with another mitogen-activated protein kinase (MEK) inhibitor within two months of first dose of REC-4881 2. Left ventricular ejection fraction (LVEF) \<50% as measured by echocardiogram (ECHO) or multigated acquisition (MUGA) scan

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APC gene mutation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

APC gene mutation AXIN1 gene mutation Solid tumor

Contacts and locations

Locations

  • American Oncology Partners of Maryland, PA

    Bethesda, Maryland, 20817, United States

  • Avera Cancer Institute

    Sioux Falls, South Dakota, 57105, United States

  • Cancer Specialists of North Florida

    Fleming Island, Florida, 32003, United States

  • Eastern Connecticut Hematology & Oncology Associates

    Norwich, Connecticut, 06360, United States

  • Hunterdon Hematology Oncology

    Hillsborough, New Jersey, 08844, United States

  • Mary Crowley Cancer Research Centers

    Dallas, Texas, 75231, United States

  • Medical Oncology Hematology Consultants

    Newark, Delaware, 19713, United States

  • Mission Cancer And Blood

    Des Moines, Iowa, 50314, United States

  • Rocky Mountain Cancer Centers

    Denver, Colorado, 80218, United States

  • Saint Luke's Hospital

    Kansas City, Missouri, 64111, United States

  • Sansum Clinic

    Santa Barbara, California, 93105, United States

  • Sharp Memorial Hospital

    San Diego, California, 92123, United States

  • Virginia Cancer Specialists

    Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.